

VICPLAS INTERNATIONAL LTD
(UEN 199805362R)
Incorporated in the Republic of Singapore
("Company / VIL")

MINUTES OF THE TWENTY-THIRD ANNUAL GENERAL MEETING ("AGM") OF THE COMPANY HELD BY ELECTRONIC MEANS PURSUANT TO THE COVID-19 (TEMPORARY MEASURES) (ALTERNATIVE ARRANGEMENTS FOR MEETINGS FOR COMPANIES, VARIABLE CAPITAL COMPANIES, BUSINESS TRUSTS, UNIT TRUSTS AND DEBENTURE HOLDERS) ORDER 2020 ON WEDNESDAY, NOVEMBER 24TH, 2021 AT 3.00 P.M.

Board of Directors (attended in person and via live audio-visual webcast)

Mr Yeo Wico	: Non-Executive Independent Chairman
Mr Ng Cher Yan	: Non-Executive Independent Director
Mr Ng Beng Tiong	: Non-Executive Independent Director
Mrs Jane Rose Philomene Gaines-Cooper	: Non-Executive Director
Mr Christopher Paul Lee	: Non-Executive Director

Senior management (attended in person and via live audio-visual webcast)

Mr Eric Cheng	: Group Chief Executive Officer
Mr Walter Tarca	: President of Medical Devices Segment
Mr Jay Cheng	: Group Operations Director
Ms Gan Ying Hui	: Chief Financial Officer

In attendance (attended via live audio-visual webcast)

Ms Christine Chan	: Legal Adviser, Allen & Gledhill LLP
Ms Celeste Yao	: Legal Adviser, Allen & Gledhill LLP
Mr Ronny Chandra	: Auditor, Deloitte & Touche LLP
Ms Esther Au	: Company Secretary

Shareholders (attended via live audio-visual webcast)

As set out in the attendance records maintained by the Company

1. Introduction

The Chairman, Mr Yeo Wico, welcomed the shareholders and attendees to the AGM. The Chairman introduced the members of the Board, the senior management team, the Company's legal adviser, the Company's auditor and the Company's secretary.

2. Quorum

As a quorum was present, the Chairman called the AGM to order.

3. Notice

The notice convening the AGM, proxy form, annual report and circular of the Company were sent to the shareholders of the Company by electronic means via publication on the Singapore Exchange Securities Trading Limited ("SGX-ST") on November 2, 2021 and were also made available on the Company's website.

4. Corporate Presentation

Before the meeting proceeded with the business of the AGM, a Corporate presentation was presented by Mr Jay Cheng, Ms Gan Ying Hui and Mr Walter Tarca. A copy of the Corporate presentation was published on the SGX-ST website on November 24, 2021 (Announcement Reference: SG211102MEETKO4B) and a copy is also attached hereto.

5. Live Questions & Answers (“Q&A”) session

After the conclusion of the Corporate presentation, the Chairman opened the floor for the ‘live’ Q&A session. There were no questions received from shareholders of the Company during the ‘live’ Q&A session.

6. Voting

In view of the COVID-19 (Temporary Measures) Act 2020 and related order on the conduct of general meetings, the Chairman informed that all votes on the resolutions tabled at the AGM would be by proxy. Shareholders of the Company voted by appointing the Chairman of the AGM as their proxy. All resolutions tabled at the AGM were voted by poll based on proxy forms that were submitted within 72 hours before the AGM. The validity of the proxies submitted by shareholders of the Company within the deadline of 3.00 p.m. on November 21, 2021, had been reviewed and the votes of all such valid proxies had been counted by B.A.C.S. Private Limited, the polling agent, and verified by Finova BPO Pte Ltd, the Scrutineer appointed by the Company.

The Chairman proceeded to the items on the agenda for the AGM.

Ordinary Business

7. Ordinary Resolution No.1
Directors’ Statement and Audited Financial Statements

The first item on the agenda was to receive and adopt the Directors’ Statement and the Audited Financial Statements of the Company for the financial year ended July 31, 2021 and the Auditor’s Report thereon.

The votes had been counted and verified by the Scrutineer and the results of the poll were as follows:

RESULTS	FOR	AGAINST	TOTAL
VOTE	360,762,669	0	360,762,669
PERCENTAGE	100.00%	0.00%	100.00%

The Chairman declared Resolution No. 1 carried.

8. Ordinary Resolution No. 2
Final (one-tier tax exempt) dividend of S\$0.0045 per share

The Chairman informed shareholders that the Directors had recommended the payment of a final (one-tier tax exempt) dividend of S\$0.0045 per share for the year ended July

31, 2021 and if approved, would be paid on January 21, 2022 to shareholders whose names appear in the Register of Members of the Company on January 11, 2022.

The votes had been counted and verified by the Scrutineer and the results of the poll were as follows:

RESULTS	FOR	AGAINST	TOTAL
VOTE	360,762,669	0	360,762,669
PERCENTAGE	100.00%	0.00%	100.00%

The Chairman declared Resolution No. 2 carried.

9. Ordinary Resolution No. 3
Directors' Fees

Ordinary Resolution No. 3 relates to the payment of S\$270,411 as fees to the Directors of the Company for the year ended July 31, 2021.

The votes had been counted and verified by the Scrutineer and the results of the poll were as follows:

RESULTS	FOR	AGAINST	TOTAL
VOTE	360,735,869	26,800	360,762,669
PERCENTAGE	99.99%	0.01%	100.00%

The Chairman declared Resolution No. 3 carried.

10. Ordinary Resolution No. 4
Re-election of Mr Ng Beng Tiong as a Director of the Company

Ordinary Resolution No. 4 relates to the re-election of Mr Ng Beng Tiong, who retires as a Director of the Company pursuant to Article 119 of the Company's Constitution. Mr Ng Beng Tiong had consented to continue in office. The Nominating Committee ("**NC**") of the Company (with Mr Ng Beng Tiong abstaining) had recommended that he be re-elected at this meeting. If re-elected, Mr Ng Beng Tiong will remain as an Independent Non- Executive Director and a member of the Audit and Risk Committee ("**ARC**") of the Company.

The votes had been counted and verified by the Scrutineer and the results of the poll were as follows:

RESULTS	FOR	AGAINST	TOTAL
VOTE	360,762,669	0	360,762,669
PERCENTAGE	100.00%	0.00%	100.00%

The Chairman declared Resolution No. 4 carried.

11. Ordinary Resolution No. 5
Re-election of Mr Yeo Wico as a Director of the Company

As Ordinary Resolution No. 5 concerned the re-election of the Chairman as a Director of the Company, he handed the proceedings over to a fellow Director, Mr Ng Cher Yan.

Ordinary Resolution No. 5 relates to the re-election of Mr Yeo Wico, who retires as a Director of the Company pursuant to Article 115 of the Company's Constitution. Mr Yeo Wico had consented to continue in office. The NC (with Mr Yeo Wico abstaining) had recommended that he be re-elected at this meeting. If re-elected, Mr Yeo Wico will remain as the Chairman of the Board, the Chairman of the NC and a member of each of the ARC, the Remuneration Committee ("RC") and the Strategy Committee of the Company.

The votes had been counted and verified by the Scrutineer and the results of the poll were as follows:

RESULTS	FOR	AGAINST	TOTAL
VOTE	349,490,931	0	349,490,931
PERCENTAGE	100.00%	0.00%	100.00%

Mr Ng Cher Yan declared Resolution No. 5 carried and he handed the proceedings back to the Chairman.

12. Ordinary Resolution No. 6
Re-election of Mr Ng Cher Yan as a Director of the Company

Ordinary Resolution No. 6 relates to the re-election of Mr Ng Cher Yan, who retires as a Director of the Company pursuant to Article 115 of the Company's Constitution. Mr Ng Cher Yan had consented to continue in office. The NC (with Mr Ng Cher Yan abstaining) had recommended that Mr Ng Cher Yan be re-elected at this meeting. If re-elected, Mr Ng Cher Yan would remain as the Chairman of the ARC, the Chairman of the RC and a member of the NC of the Company.

The votes had been counted and verified by the Scrutineer and the results of the poll were as follows:

RESULTS	FOR	AGAINST	TOTAL
VOTE	360,762,669	0	360,762,669
PERCENTAGE	100.00%	0.00%	100.00%

The Chairman declared Resolution No. 6 carried.

13. Ordinary Resolution No. 7
Re-appointment of Auditor

Ordinary Resolution No. 7 relates to the re-appointment of Deloitte & Touche LLP as the Company's Auditor and to authorise the Directors of the Company to fix their remuneration. Deloitte & Touche LLP had expressed their willingness to accept re-appointment and the ARC had recommended that they be re-appointed at this meeting.

The votes had been counted and verified by the Scrutineer and the results of the poll were as follows:

RESULTS	FOR	AGAINST	TOTAL
VOTE	360,762,669	0	360,762,669
PERCENTAGE	100.00%	0.00%	100.00%

The Chairman declared Resolution No. 7 carried.

Special Business

14. Ordinary Resolution No. 8
"Tier-1" approval for Mr Yeo Wico

Rule 210(5)(d)(iii) of the Listing Manual of the SGX-ST (which will take effect from January 1, 2022), provides that an Independent Director who has served for more than 9 consecutive years would not be considered as independent unless the company has sought prior approval from shareholders, via 2 separate resolutions, for his or her continued appointment as an Independent Director. The 2 separate resolutions would have to be voted by (i) all shareholders ("**Tier-1**") and (ii) shareholders (excluding Directors and CEO of the company, and their associates) ("**Tier-2**"). If Tier-1 and Tier-2 approvals are obtained, such approvals would remain in force until the earlier of (i) retirement or resignation of such director, as the case may be, and (ii) the conclusion of the third Annual General Meeting of the company following the passing of the resolutions under Tier-1 and Tier-2.

As Ordinary Resolution Nos. 8 and 9 concerned the continued appointment of the Chairman as an Independent Director of the Company, he handed the proceedings over to a fellow Director, Mr. Ng Cher Yan.

Ordinary Resolution No. 8 was to seek shareholders' approval for Mr Yeo Wico's continued appointment as an Independent Director under Tier 1.

The votes had been counted and verified by the Scrutineer and the results of the poll were as follows:

RESULTS	FOR	AGAINST	TOTAL
VOTE	349,490,931	900	349,491,831
PERCENTAGE	100.00%	0.00%	100.00%

Mr Ng Cher Yan declared Resolution No. 8 carried.

15. Ordinary Resolution No. 9

“Tier-2” approval for Mr. Yeo Wico

Ordinary Resolution No. 9 was to seek shareholders’ approval for Mr Yeo Wico’s continued appointment as an Independent Director under Tier 2.

The votes had been counted and verified by the Scrutineer and the results of the poll were as follows:

RESULTS	FOR	AGAINST	TOTAL
VOTE	13,440,303	900	13,441,203
PERCENTAGE	99.99%	0.01%	100.00%

Mr Ng Cher Yan declared Resolution No. 9 carried and he handed the proceedings back to the Chairman.

16. Ordinary Resolution No. 10
“Tier-1” approval for Mr Ng Cher Yan

Ordinary Resolution No. 10 was to seek shareholders’ approval for Mr Ng Cher Yan’s continued appointment as an Independent Director under Tier 1.

The votes had been counted and verified by the Scrutineer and the results of the poll were as follows:

RESULTS	FOR	AGAINST	TOTAL
VOTE	360,762,669	900	360,763,569
PERCENTAGE	100.00%	0.00%	100.00%

The Chairman declared Resolution No. 10 carried.

17. Ordinary Resolution No. 11
“Tier-2” approval for Mr Ng Cher Yan

Ordinary Resolution No. 11 was to seek shareholders’ approval for Mr Ng Cher Yan’s continued appointment as an Independent Director under Tier 2.

The votes had been counted and verified by the Scrutineer and the results of the poll were as follows:

RESULTS	FOR	AGAINST	TOTAL
VOTE	13,440,303	900	13,441,203
PERCENTAGE	99.99%	0.01%	100.00%

The Chairman declared Resolution No. 11 carried.

18. Ordinary Resolution No. 12
Authority to allot and issue shares and convertible instruments

Pursuant to Section 161 of the Companies Act, Cap. 50 and the Listing Rules of the SGX-ST, shareholders' approval was required to authorise the Directors of the Company to issue new shares and/or grant instruments convertible into shares up to the limit specified in the Ordinary Resolution No. 12. The details of Ordinary Resolution No. 12 were set out in the notice convening the AGM.

The votes had been counted and verified by the Scrutineer and the results of the poll were as follows:

RESULTS	FOR	AGAINST	TOTAL
VOTE	360,591,869	170,800	360,762,669
PERCENTAGE	99.95%	0.05%	100.00%

The Chairman declared Resolution No. 12 carried.

19. Ordinary Resolution No. 13
Renewal of the Interested Person Transactions ("IPT") Mandate

Ordinary Resolution No. 13 relates to the renewal of the IPT Mandate, details of which were set out in the Appendix of the Company's circular to shareholders dated November 2, 2021.

The votes had been counted and verified by the Scrutineer and the results of the poll were as follows:

RESULTS	FOR	AGAINST	TOTAL
VOTE	53,056,028	0	53,056,028
PERCENTAGE	100.00%	0.00%	100.00%

The Chairman declared Resolution No. 13 carried.

20. Ordinary Resolution No. 14
Renewal of the Share Purchase Mandate

Ordinary Resolution No. 14 relates to the renewal of the Share Purchase Mandate, details of which were set out in the Company's circular to shareholders dated November 2, 2021.

The votes had been counted and verified by the Scrutineer and the results of the poll were as follows:

RESULTS	FOR	AGAINST	TOTAL
VOTE	360,762,669	0	360,762,669
PERCENTAGE	100.00%	0.00%	100.00%

The Chairman declared Resolution No. 14 carried.

21. Ordinary Resolution No. 15
Authority to issue new shares pursuant to the Vicplas International Ltd Scrip Dividend Scheme

Ordinary Resolution No. 15 was to seek shareholders' approval for the Directors of the Company to allot and issue shares in the capital of the Company pursuant to the Vicplas International Ltd Scrip Dividend Scheme to eligible shareholders who, in respect of the qualifying dividend, have elected to receive scrip in lieu of the cash amount of that qualifying dividend.

The votes had been counted and verified by the Scrutineer and the results of the poll were as follows:

RESULTS	FOR	AGAINST	TOTAL
VOTE	360,762,669	900	360,763,569
PERCENTAGE	100.00%	0.00%	100.00%

The Chairman declared Resolution No. 15 carried.

22. Ordinary Resolution No. 16
Adoption of the Vicplas International Share Option Plan 2021

The last item on the agenda was to seek shareholders' approval for the adoption of the Vicplas International Share Option Plan 2021 ("**VISOP 2021**") and to allot and issue ordinary shares of the Company pursuant to the exercise of options granted under VISOP 2021, provided that the aggregate number of new shares which may be issued pursuant to options granted under the VISOP 2021 does not exceed 15% of the total number of shares of the Company (excluding treasury shares and subsidiary holdings) from time to time. The details of the VISOP 2021 were set out in the Company's circular dated November 2, 2021.

The votes had been counted and verified by the Scrutineer and the results of the poll were as follows:

RESULTS	FOR	AGAINST	TOTAL
VOTE	293,613,744	144,900	293,758,644
PERCENTAGE	99.95%	0.05%	100.00%


The Chairman declared Resolution No. 16 carried.

23. Conclusion

There being no other business, the Chairman declared the AGM closed at 3.45 p.m. He thanked all for attending the AGM and he wished them well and to stay safe.

CONFIRMED AS A RECORD OF THE PROCEEDINGS OF THE MEETING

**YEO WICO
CHAIRMAN**



VICPLAS INTERNATIONAL LTD

The parent company of
Forefront Medical and Vicplas Holdings



Corporate Presentation

24 November 2021

DISCLAIMER

This presentation is for information purposes only and does not constitute or form part of an offer, solicitation, recommendation or invitation for the sale or purchase or subscription of securities in Vicplas International Ltd (the "Company" or "Vicplas"). No part of it nor the fact of its presentation shall form the basis of or be relied upon in connection with any investment decision, contract or commitment whatsoever.

The information and opinions in this presentation are provided as at the date of this document (unless stated otherwise) and are subject to change without notice, their accuracy are not guaranteed, represented or warranted and they may not contain all material or relevant information concerning the Company or the Company and its subsidiaries (collectively, the "Group"). Neither the Company nor its related corporations, affiliates, nor any of their respective directors, officers, partners, employees, agents, representatives or advisers make any representation or warranty regarding, and assumes no responsibility, obligation or liability whatsoever (in negligence or otherwise) for, the accuracy or completeness of, or any errors or omissions in, any information contained herein nor for any loss howsoever arising from any use of this presentation. Further, nothing in this presentation should be construed as constituting legal, business, tax, investment or financial advice.

The information contained in this presentation includes historical information about and relevant to the Group or the Group's businesses that should not be regarded as an indication of the future performance or results of the Group or such businesses. Certain statements in this presentation constitute "forward-looking statements". These forward-looking statements are based on the current views of the Group concerning future events, and necessarily involve risks, uncertainties and assumptions, which may change over time. These statements can be recognised by the use of words such as "expects", "plans", "will", "estimates", "projects", "intends" or words of similar meaning. Actual future performance could differ materially from these forward-looking statements, and no assurance is given that future events will occur, that projections will be achieved, or that the Group's views are correct, nor should you rely on these forward-looking statements for any purpose. The Company does not assume any responsibility to amend, modify or revise any forward-looking statements, on the basis of any subsequent developments, information or events, or otherwise, subject to compliance with all applicable laws and regulations and/or the rules of the Singapore Exchange Securities Trading Limited and/or any other regulatory or supervisory body or agency.



CONTENTS

About
Us

COMPANY OVERVIEW
FINANCIAL INFORMATION

Our
Companies


FOREFRONT MEDICAL
VICPLAS HOLDINGS

COMPANY OVERVIEW

VICPLAS INTERNATIONAL LTD



GLOBAL PRESENCE



Business Segments

Medical devices segment

Forefront Medical designs, develops and manufactures sterile and non-sterile medical devices

Pipes & pipe fittings segment

Vicplas Holdings (“Vicplas Pipes”) manufactures and distributes piping systems for diverse industries


Total employees : 1,000+ worldwide

Accreditations

The subsidiaries in the pipes and pipe fittings segment have ISO9001:2015 quality certifications.

The subsidiaries in the medical devices segment have quality certifications of EN ISO13485:2016 and, with the exception of XentiQ (Pte.) Ltd, are registered under the United States Food and Drug Administration (FDA) as a “contract manufacturer for medical devices” and Accreditation certificate of foreign medical device manufacturer from Japan Ministry of Health, Labour and Welfare. Forefront Medical Investment Pte. Ltd. additionally has a Class A, B, C, D Medical Device manufacturer license registered under Health Science Authority (HSA) Singapore and Forefront Medical Technology (Jiangsu) Co., Ltd additionally has a Class II Medical Device Manufacturing License in China.

VICPLAS GROWTH JOURNEY



FINANCIAL INFORMATION

VICPLAS INTERNATIONAL LTD




REVENUE GROWTH

We achieved steady growth over the past five years, with a CAGR of 15.7%.

Forefront Medical's contribution to the Group's revenue has grown from 39.1% in FY2017 to 70.4% in FY2021 and is expected to continue leading our transformation into a medical-focused group.

Vicplas Pipes continues to be an industry leader in the mature pipes and pipe fittings segment.


Together our two segments work in a complementary manner with Vicplas Pipes providing a stable foundation for the Group while Forefront Medical pursues accelerated growth in a growing medical devices segment.



PROFIT GROWTH

Our profit growth rate has trended higher compared to the revenue growth rate.

This has been supported largely by an increasing contribution from Forefront Medical.




SEGMENTAL RESULTS

Forefront Medical continues its growth momentum, recording more than 3X increase in revenue and significant improvement in segmental results over the past five years.

Vicplas Pipes was inevitably impacted by the construction industry slowdown in FY2020 due to the pandemic. However, it has since begun to recover. In FY2021, its revenue returned to 96% of FY2019's pre-pandemic levels.

*The segmental results of the medical devices segment and pipes and pipe fittings segment are before corporate, interest and tax expenses as set out in Note 33 of the FY2021 Annual Report.




RE-INVESTING FOR GROWTH

We take a long-term view of success.

Our balanced approach to rewarding shareholders and maintaining sufficient capital in the business to support long-term growth plans, especially in the medical devices segment, reflects this. This is also prudent, given the current macro-economic risks.

For FY2021, the directors have recommended a final dividend of 0.45 Singapore cents per share. This is a 20% increase from FY2020 as a result of higher net profit after tax recorded.

The growth in Return on Equity is testament to our approach of re-investing in the business for growth, as more opportunities emerge.



	FY2017	FY2018	FY2019	FY2020	FY2021
Dividend Per Share (Singapore Cents)	0.75	0.75	0.75	0.375	0.45 *
Debt to Equity Ratio	0.02	0.05	0.14	0.14	0.19
Return on Equity	5.5%	6.1%	6.9%	7.9%	14.5%

* Subject to the approval by shareholders at the AGM on 24 November 2021

MEDICAL DEVICES

Walter Tarca
President

FOREFRONT
MEDICAL

WWW.FOREFRONTMEDICAL.COM

OUR VISION

To be a leading global medical device manufacturing partner with solutions that are preferred by product owners

- 100% focused on manufacturing quality devices for the medical device industry
- Global customer base in five continents
- More than 900 employees
- Committed to providing our customers and their patients with innovative and cost-effective medical devices to enable continuous improvements in healthcare





Singapore – Corporate HQ



Changzhou, China



Xiamen, China



GLOBAL PRESENCE

Manufacturing Sites

- Singapore – Corporate HQ (7,410m²)
- Xiamen, China (7,000m²)
- Changzhou, China (7,024m²)
- Changzhou, China (7,000m² extension opening in 2022)
- Kington, UK (2,600m²)

Commercial Offices

- Singapore
- Shanghai, China
- Connecticut, USA
- Kington, UK

OPPORTUNITIES


A GROWING INDUSTRY

The MedTech contract manufacturing market is expected to grow by an average of 11.4% year-on-year through 2025.

Key drivers:

- Ageing population
- Increased demand for improved healthcare in developing markets
- Increased willingness by product owners to outsource manufacturing to trusted partners that can fully support product and process innovation

MedTech CDMO Market by Application: 2019-2025e (US\$B)



FY2021 HIGHLIGHTS

- Emphasis placed on building a company that is flexible, resilient and resourceful to build long term partnerships and sustainability for our stakeholders.
- S\$1.5 million refurbishment of Singapore plant clean rooms created more opportunities and flexibility in winning new customers and projects.
- Continuing improvement in our capabilities sees more project awards from existing and new customers.
- In the challenging early stages of the COVID-19 pandemic, we introduced safety protocols that kept our team safe and kept delivery disruptions for our global customers to a minimum. COVID-19 vaccination rates in all our plants exceed 95% currently.



OUR VALUE PROPOSITION TO CUSTOMERS



IN-HOUSE CAPABILITIES

FROM CONCEPT TO MANUFACTURING



PediGuard
for Spinal
Surgery



Feeding PVC
Tube with
Tungsten



Laryngeal
Mask with
LSR Cuff



Reinforced
Extruded
Silicone Tube

Design & Development	<ul style="list-style-type: none"> Product Concept & Realisation Electronics, Software, Metal Parts 	
Rapid Prototyping		
Plastic & LSR Tooling	<ul style="list-style-type: none"> In-house Toolroom & Design Team Insert Mould 	<ul style="list-style-type: none"> Micro Mould 2K Mould Stack Mould
Moulding Capabilities	<ul style="list-style-type: none"> Wide Range of Materials Injection Extrusion 	<ul style="list-style-type: none"> Injection Blow Extrusion Blow
Production	<ul style="list-style-type: none"> Cleanroom Facility Pilot/Trial Run 	<ul style="list-style-type: none"> Low Mix High Volume High Mix Low Volume
Quality	<ul style="list-style-type: none"> ISO 13485 FDA 510K 	<ul style="list-style-type: none"> CE Mark IQ/OQ/PQ
Assembly	<ul style="list-style-type: none"> Manual Assembly High Speed Automation 	
Secondary Processes	<ul style="list-style-type: none"> Hydrophilic Coating RF Tipping & Forming 	<ul style="list-style-type: none"> Pad Printing Bonding & Welding
Packing	<ul style="list-style-type: none"> Rigid Blister Soft Blister 	<ul style="list-style-type: none"> Tyvek Pouch Pallet Optimisation
Sterillization	<ul style="list-style-type: none"> EtO Gamma 	<ul style="list-style-type: none"> Autoclave E-Beam

OUR BUSINESS

OUR MEDICAL DEVICE PORTFOLIO

- Vascular
- Pharmaceutical Bottles
- Surgical Devices
- Respiratory
- Orthodontics
- Airway Management
- PPE Gowns / Nasal Swabs
- Endoscopy
- Drug Delivery
- Diagnostics



MOULDING & EXTRUSION CAPABILITIES

INJECTION MOULDED MEDICAL COMPONENTS

- Micro-Molding
- Insert Molding
 - Plastics & Metals
- Co-Injection
- Multi-Shot Molding
- Unscrew Molding
- Tooling Capabilities
 - Stack Mold
 - Spin-Stack Mold
 - In-Mold Assembly

EXTRUSION MEDICAL TUBING COMPONENTS

- Multi-Lumen Tubes
- Braided Tubes
- Co Extrusion
- Multi Color / Layer Extrusion
- Small Bore Tubes
 - Catheters
- Specialty Tubes
 - Radio Opaque Additives
 - Added Tube



COMPLETE DEVICES

Comprised more than 90% of our volume in FY2021

SAFETY WING INFUSION SET

Injection | Secondary Process | Assembly | Packaging



Assembly Automation Line in Class 7 (10k) Assembly Cleanroom

JEJUNAL & NASO-GASTRIC FEEDING TUBE

Product Development | Injection | Extrusion | Assembly | Packaging | Sterilisation



COMPLETE DEVICES

Comprised more than 90% of our volume in FY2021


ENDOTRACHEAL TUBE

Injection | Extrusion | Blow | Assembly | Packaging | Sterilisation



FULL DEVICE – SCANBOX (AI & ORTHODONTICS)

Injection | Assembly | Packaging



OUR ESG COMMITMENT

ENVIRONMENTAL, SOCIAL AND GOVERNANCE

We endeavour to continually improve/drive long-term value for our stakeholders, customers, employees, shareholders, suppliers and the community in which we do business.

In 2021, we stepped up to help the Singapore and UK health authorities with products needed to fight Covid-19.

We are pursuing further ISO certifications in Environment and Energy Management to help address challenges which impact our environment.

We provide growing career opportunities for people in our communities who want to make a difference by supporting advances in healthcare and helping clinicians and their patients around the world.

NASOPHARYNGEAL SWABS



Clinically tested
and proven
effectiveness

Class A device
registered with
HSA, USFDA & CE



Patented tip design

Made with
biocompatible
nylon

Flexible neck
ensures ease
of use and
improved
patient comfort


PPE GOWNS



ACHIEVING OUR VISION

OUR STRATEGIC INTENT

To improve profitability by delivering great solutions for our MedTech customers and building sustainable value for all our stakeholders




FINANCIAL RESULTS

SUSTAINED YEAR-ON-YEAR GROWTH RECORD

31% increase in FY2021 revenue

54% increase in FY2021 segmental results



OUR STRATEGIC PRIORITIES

1. ACCELERATE CAPITAL INVESTMENTS

- Broaden global footprint to satisfy demand and improve flexibility for new customers
 - Changzhou extension
 - Possible new plant outside Asia (near USA)
- Implement factory I.4 initiatives to drive operational efficiencies and output improvements

2. DRIVE CAPABILITY IMPROVEMENTS & INNOVATION

- Build expanded capabilities in in-vitro diagnostics, medical extrusions and electro-mechanical devices to strengthen new revenue streams
- Continued investment in collaborative projects with MedTech product owners to expand our capabilities and drive growth

3. BUILD A HIGH-PERFORMANCE TEAM TO DRIVE GROWTH

- Continue to develop and provide opportunities for our highly engaged, tenured team delivering quality products to global markets
- Invest in additional MedTech talent pool to drive new revenue streams and manage growth

REVENUE GROWTH MOMENTUM

BUSINESS OUTLOOK

- We are optimistic about long-term growth opportunities in medical device manufacturing globally because of expected market growth and our increasing capability, but we are mindful of uncertainties in current international trading conditions.
- Forefront Medical will continue to broaden its customer base and improve its core capabilities to provide enhanced service offerings to customers, while improving efficiency at its manufacturing plants to lower costs.
- Assessing the establishment of the next medical device plant outside Asia (near USA) in order to provide operational diversity, additional space to meet growth expectations, and resilience for our customer base.
- Operations have normalised at this stage of the COVID-19 pandemic but we continue to monitor the situation closely.

PIPES & PIPE FITTINGS

Jay Cheng
Group Operations Director

VICPLAS
PIPES

WWW.VICPLAS.COM.SG

A SUSTAINABLE BUSINESS

ABOUT US

Vicplas Pipes is a leading solutions provider in the plastic pipe manufacturing industry. Our uPVC piping systems are found in a majority of residential homes across Singapore. Our market leadership is built on the quality and reliability of our products. They are commonly found in:

- **Plumbing and Electrical Works** across residential, commercial, institutional, industrial and other buildings
- **Civil Engineering Works** ranging from telecommunication and power grid pipelines to infrastructure works

OUR VALUE PROPOSITION TO CUSTOMERS

Solutions Provider



Proactively look for new product development opportunities to fill industry gaps and meet emerging needs

Operational Efficiency



Invest in new technologies and improve existing processes to enhance operational and manufacturing efficiency



Product Reliability

Conduct regular quality checks to ensure that our products meet our stringent quality standards and applicable regulatory requirements



Green Initiatives

Contribute to a cleaner and greener future by developing environmentally friendly products



Research & Development


Constantly explore new possibilities in the design and manufacture of our products

OUR CORE CAPABILITIES



Product Design

Develop practical, cost-efficient solutions that evolve with the changing needs of our customers.



Processing Techniques

Proficient across a range of polymer processing techniques and are able to offer injection, extrusion, thermal forming and fabrication processes.



Tool Fabrication

Equipped with in-house mould design and fabrication capabilities.



Materials Know-how

Extensive working knowledge of polymeric materials such as engineering plastics, specialty elastomers, composites and more.

Vicplas Pipes' products are all certified by international testing bodies to meet the industry standards of product quality.



ENVIRONMENTAL, SOCIAL AND GOVERNANCE

PIONEERING HEAVY METALS FREE PLASTIC PRODUCTS

We take pride in being the first uPVC pipe producer in Singapore to receive one Green Check Mark certification from the Singapore Green Building Council. This is the direct result of our efforts to reformulate all our plastic product lines to go heavy metals free since 2016.

We are currently pursuing the second and third Check Marks to strengthen our market leadership position.



SUPPORTING FOOD SUSTAINABILITY

We support the Singapore Green Plan, which includes targets to produce 30% of our food source locally by 2030. Building on our core capabilities in heavy metals free plastics, we have developed a range of plastic products to support indoor and vertical urban farming.



PRODUCT APPLICATIONS



BUILDINGS

Residential homes
Commercial buildings
Institutional buildings
Industrial / Others



HYDRO-AGRICULTURE

Plastic pipes
Plastic channels



CIVIL ENGINEERING

Telecommunication pipelines
Power grid pipelines
Infrastructure works

FY2021 HIGHLIGHTS

- As construction activities picked up in FY2021, we took pre-emptive measures to ensure the safety of our employees while gradually scaling up production output.
- Some of our products are manufactured in our facility in Malaysia. Given the COVID-19 situation there, we increased our inventory holding levels in Singapore to minimise the risk of supply disruptions. This, combined with our Singapore manufacturing presence, was critical in ensuring supply stability to our customers here.
- More than 95% of our employees in Singapore are fully vaccinated currently.



BUSINESS OUTLOOK

CONTINUED INDUSTRY PRESSURES

- Although the construction industry in Singapore is gradually recovering from the impact of COVID-19, labour shortages and supply chain disruptions remain major contributors to project completion delays.
- Increased operating costs and higher raw material prices are expected to continue into FY2022.

PRUDENCE AND FOCUSED GROWTH

- In view of increased competition and longer completion time required for building construction projects, the segment will continue to focus its growth on civil engineering projects and product expansion.
- We will continue to operate prudently and drive operational efficiencies through continuous improvement.

THANK
YOU

Vicplas International Ltd

Reg No: 199805362R

www.vicplas.com